The recent judgment brings clarity to families and doctors of people in vegetative states – but also raises the importance of advance care planning, says Davina Hehir, Director of Policy and Legal Strategy at Compassion in Dying. 

This truly sad case really highlights how important it is that vulnerable people are provided with ongoing, continued support to live independently, says Ellie White, Senior Policy and Campaigns Officer at Mind.

Cancer patients could lose out on vital drugs if Britain leaves the EU without a deal, pharmaceutical giant AstraZeneca has warned.

An ‘inspirational’ mother-of-two is on a personal mission to smash fundraising targets and challenge social stereotypes after being diagnosed with dementia at the age of 39.

New research from UCL out tomorrow has highlighted the difference in diagnosis rates between black ethnic groups compared to white groups in the UK. 

Denials, cover-ups and delays have led to obstructive and ignorant treatment of contaminated blood scandal campaigners, says Chris Stephens MP.

Care workers from the EU must have priority under any post-Brexit migration system or British women face having to quit their jobs to look after ageing relatives, ministers have warned.

Pressure continues to build for England to introduce an op-out organ donation scheme, writes Dods Monitoring's Sophie-Rose Feary.

Alzheimer’s Society is calling on family, friends and colleagues to unite against dementia this autumn by joining a Memory Walk. 

Co-chairs of the newly established All-Party Parliamentary Group for Medicinal Cannabis call on Sajid Javid to continue to act swiftly on the issue of medicinal cannabis and allow whole plant cannabis oils to be available under prescription in the UK so long as they are manufactured to the well regarded Good Manufacturing Practice (GMP) standard.

The Department for Transport has announced that it is extending the Blue Badge scheme so that more people with ‘invisible’ health problems, such as autism and mental health problems, can now apply.

Research presented at Alzheimer’s Association International Conference (AAIC) has found that 10 minutes of social interaction a day helps improve wellbeing for people with dementia in care homes.

Research presented at Alzheimer’s Association International Conference (AAIC) today has found that the cholesterol control drug, gemfibrozil, reduces levels of amyloid and brain inflammation in mice.

Research presented at Alzheimer’s Association International Conference (AAIC) today shows that a genetic variant of the PLCG2, a gene previously associated with risk of Alzheimer’s Disease, may reduce the risk of developing some dementias and healthy ageing.

The Falkland Islands have today been shown to be a compassionate, sensible and progressive society which cares deeply about its terminally ill citizens and rightly feels that they deserve better, says Dignity in Dying.

Sajid Javid has announced that medical cannabis will be available on prescription, following the high-profile case of Billy Caldwell.

Research presented at Alzheimer’s Association International Conference (AAIC) has found evidence in support of the “amyloid hypothesis”. BAN2401 drug treatment was found to reduce amyloid in the brain, a protein associated with Alzheimer’s disease.

Concerns have been raised over the low number of people with diabetes who have been prescribed new “game-changing” technology following the results of a nationwide investigation.

A phase 1 trial reported in Nature Communications today has found that blood‒brain barrier  (BBB) can be non-invasively and reversibly opened in five patients with Alzheimer’s disease. The early results suggest that the procedure is safe, but it is unclear from the research how effective this is.

The public overwhelmingly supports letting nurses from the European Union work in the UK after Brexit, a new poll has found.

The 'disproportionally high' demand for BAME organ donations coupled with the 'extremely low' supply has created a serious health crisis, writes Eleanor Smith MP. 

Research presented at Alzheimer’s Association International Conference (AAIC) today shows that a study of the immunotherapy treatment Crenezumab has found it can reduce levels of the protein amyloid, associated with dementia.

Research presented at Alzheimer’s Association International Conference (AAIC) today shows that a potential new drug to treat Alzheimer’s disease, Lanabecestat, has failed a phase 2/3 trial. Pharmaceutical giants Eli Lilly and AstraZeneca have announced that they are ending two phase 3 trials into the drug.

Research presented at Alzheimer’s Association International Conference (AAIC) today shows that air pollution could have an effect on cognitive ageing. Results showed that exposure to air pollution in early life was linked to cognitive ageing, but it had little effect in later life.